With the looming threat of these supply lines being disrupted by TRIPS+ provisions that are likely to be demanded of the Indian Government by FTA negotiators from the European Union and Japan we request that the Indian Government stand firm on their position of refusing all TRIPS+ provision that maybe included in any final agreement.
Poor people in India and other developing countries may lose access to affordable generic drugs as part of free-trade negotiations between India and the European Union, a medical advocacy group said on Friday.
Far-reaching provisions on the patenting of medicine have been inserted into a controversial free trade agreement between the European Union and Colombia and Peru.
The eighth round of the FTA talks which took place in Mumbai last week have been strongly criticised in India for their secrecy and lack of consultation with the national parliament and state governments.
Whichever FTA is signed first — Japan’s or the EU’s — will put pressure on the other pair of negotiators to reach pragmatic compromises. The race for India is on.
The Peruvian Network for a Just Globalization says that both public opinion, as well as members of Congress, have to make sure that no conditions that restrict access to medicines for thousands of
Peruvians are included in the text of the EU-Peru trade agreement.
Amid fresh talks on the India-Japan free trade agreement (FTA), concerns are being expressed about certain measures that could hamper generic drugs and access to medicines.
The European Union on Friday said it would prefer to resolve two commercial disputes with India without engaging in a legal battle at the World Trade Organisation (WTO). The first dispute involves seizure of Indian generic drugs in transit at some EU-based ports, including Amsterdam, which were bound for certain third world countries, on the grounds of patents infringement.
The bilateral free trade agreements (FTAs) India is negotiating with Japan and the European Union (EU) can lead to a sharp rise in the cost of medicines, a network of civil society groups has warned.
The European Union’s demands on India to take on higher intellectual property (IP) standards, if adopted, could spell disaster for the supply of low-cost generic medicines, undermine India’s development and set a significant precedent for the future of IPR protection globally, cautioned Dr Carlos M. Correa, an expert on IP and the WTO TRIPS Agreement.
What is slowly emerging is the beginning of a composite oppositition to FTAs in India.
The negotiating texts so far known do indicate that India is resisting many aspects of the EU demands of higher IPRs standards. Analysis by Carlos Correa.
Confronted by a potential pandemic, negotiations for FTAs with
the European Union are taking place in Brussels this week, where more
extensive protections for intellectual property will be discussed.
The EU is more aggressive in its approach to intellectual property in trade agreements than the United States, MEPs learn
The free trade agreement the EU has proposed to Asean deliberately undermines the Doha Declaration on patents and public health.
As negotiations for the South Korea-European Union free trade agreement (Korea-EU FTA) race into their final stages, the inner workings are starting to come to light.
The Peruvian Foreign Trade and Tourism Ministry said Thursday that Peru will not accept raise in medicine prices in the second round of negotiations for a Free Trade Agreement with the European Union..
As the sixth round of negotiations related to the EU-India Free Trade Agreement (FTA) got underway on Tuesday, the police detained a couple of representatives of public interest groups during a peaceful protest in front of the office of the European Commission (EC).
The Free Trade Agreement or the Association Agreement the European Union is promoting with two of the four countries member of the Andean Community of Nations (CAN) risks the continuity of this bloc, but it also represents a threat to access to medications and health of the Andean peoples.
The proposed EU-Asean free trade policy on intellectual property rights protection is too sweeping, says a consumer group.